Background: Previous case-control studies have reported inconsistent findings regarding the association between proton pump inhibitor (PPI) use and colorectal cancer (CRC) risk. We investigated these associations using meta-analysis.
INTRODUCTION
Proton pump inhibitors (PPIs) are potent medications to inhibit gastric acid production, 1) and are widely used by physicians for effective management of gastrointestinal disorders including peptic ulcer disease and gastroesophageal reflux disease (GERD). 2, 3) Although long-term use of these drugs is considered safe, concern has risen regarding the possible link between PPIinduced hypergastrinemia and gastrointestinal cancers, including colorectal cancer (CRC). [4] [5] [6] [7] Serum gastrin may promote the animal studies showed that hypergastrinemia may promote adenoma progression, which is the precursor of colorectal cancer. 8, 9) Recently, several large, nested, case-control studies were performed to clarify the relationship between PPI use and colorectal cancer risk. Most previous studies have shown that use of PPI in clinical practice was not associated with increased risk of colorectal cancer. [10] [11] [12] [13] However, one study in the United Kingdom showed a significant association between <2 years of PPI therapy and the risk of colorectal cancer in univariate analysis. 12) One study in Denmark also showed a marginal increased risk of colorectal cancer among those who had taken PPIs recently. 13) As the total number of PPI prescriptions are continuously increasing world-wide and many patients require long-term PPI therapy, 1, 2) potential adverse effects of PPI, including its effect on colorectal cancer risk, should be evaluated. Therefore, in the current study,
we estimated the magnitude of the associations between PPI use and increased risk of colorectal cancer via meta-analysis of epidemiological studies.
METHODS

Literature Search
We searched MEDLINE (PubMed, inception for the outcome factors. We also scanned the bibliographies of relevant articles in order to identify additional studies. Only articles written in English were included in the current study.
Selection Criteria
We included observational studies and clinical trials that met all of the following criteria: 1) case-control studies, cohort studies, and randomized controlled trials. Although we planned to include epidemiological studies such as prospective cohort studies or randomized controlled trials, to date, no randomized controlled trials or cohort studies have been published. We, therefore, decided to include only case-control studies in the current study.
We also included studies which 2) investigated the associations between the use of proton pump inhibitors and colorectal cancer, and 3) reported outcome measures with odds ratio (OR) and 95% confidence interval (CI), or values in cells of a 2 × 2 table
(from which ORs could be calculated).
Selection of Relevant Studies
All studies retrieved from databases and bibliographies were independently evaluated by two authors of this paper (Ahn JS and Park SM). Disagreements between evaluators were resolved by discussion or in consultation with a third author (Eom CS).
Assessment of Methodological Quality
We assessed the methodological quality of included studies based on the Newcastle-Ottawa Scale (NOS) for the quality of case-control studies in meta-analyses. 14) The NOS for casecontrol studies consists of 8 items with three subscales: selection of cases and controls (4 items), comparability of cases and controls (1 item), and exposure (3 items). A "star" system of the NOS (range, 0 to 9 stars) has been developed for the assessment:
each study can be awarded a maximum of one star for each numbered item within the selection and exposure categories, while a maximum of two stars can be given for the comparability category. In the current study, we considered a study awarded 7
or more stars as a high quality study, as standard criteria have not been established. The mean value for the 5 studies assessed was 8.4 stars.
Main and Sensitivity Analyses
We investigated the association between the use of proton pump inhibitors (used vs. never or rarely used, if possible) and the risk of colorectal cancer by using adjusted data as the main analysis. We also performed sensitivity analyses by methodological quality (high or low quality), cumulative duration of PPI use (≥ 1 year and ≥ 5 years), and adjusted for other CRC risk factors including nonsteroidal antiinflammatory drug (NSAID)s/aspirin and body mass index.
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Statistical Analyses
To compute a pooled OR with 95% CI, we utilized the adjusted OR and 95% CIs reported in each article whenever possible. Heterogeneity in results across studies was assessed by using Higgins I 2 , which measures the percentage of total variation across studies. 15) Negative values of I 2 were set at zero so that I 2 exists between 0% (no observed heterogeneity) and 100% (maximal heterogeneity). An I 2 value greater than 50% was considered as indicative of substantial heterogeneity.
We estimated a pooled OR with 95% CI based on both fixed-effects and random-effects models. When substantial heterogeneity was not observed (i.e., if I 2 ≤ 50%), the pooled estimate calculated based on the fixed-effects model using the Woolf's (inverse variance) method was reported. When substantial heterogeneity was observed (i.e., if I 2 > 50%), the pooled estimate was calculated based on the random-effects model using the DerSimonian and Laird. 16) We were unable to assess publication bias of the studies included in the final analysis using Begg's funnel plot asymmetry and Egger's test, because when there are few studies, the power of the tests is too low to distinguish chance from real asymmetry. We used Stata SE ver.
10.1 (Stata Co., College Station, TX, USA) for statistical analysis. Figure 1 shows a flow diagram of how we identified relevant studies. A total of 737 articles were identified by searching 3 databases and through hand-searching relevant bibliographies. We excluded 70 duplicate articles and an additional 652 articles that did not satisfy the selection criteria. We reviewed the full texts of the remaining 15 articles. Among these, 10 articles were excluded in the final analysis. The main reasons for exclusion of studies during the final review were as follows (n = 10): data on mortality only (n = 1), 17) data on colorectal polyp only (n = 3), [18] [19] [20] or review article (n = 6). 7, [21] [22] [23] [24] [25] The remaining 5 case-control studies were included in the final analysis.
RESULTS
Identification of Relevant Studies
10-13,26)
Characteristics of Studies Included in the Final Analysis
In the 5 case-control studies, we identified a total of 120,091 participants, 9,514 cases, and 110,577 controls. Table 1 
Overall Use of PPI and Risk of CRC
As shown in Figure 2 , the overall use of PPI (used vs. never or rarely used) was not significantly associated with the risk of CRC 
9
: A "star" system of the Newcastle-Ottawa Scale (NOS) has been developed for the methodological quality assessment: each study can be awarded a maximum of one star for each numbered item within the selection and exposure categories, while a maximum of two stars can be given for the comparability category. *When there was no significant difference in the response rate between both groups by using a chi-square test (P > 0.05), one point was awarded.
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in a fixed-effects model meta-analysis of all 5 case-control studies (OR, 1.08; 95 % CI, 0.96 to 1.20; I 2 = 3.5%). Table 2 shows the methodological quality of studies included in the final analysis, based on the Newcastle-Ottawa Scale for assessing the quality of case-control studies. The range of quality scores was 6 to 9; the average score was 8.4. The high-quality studies (7 or higher) included all population-based case-control studies. As for the adjustment for other CRC risk factors, use of NSAIDs/aspirin was considered in three studies, 12, 13, 26) and body mass index was adjusted in two studies. 13, 26) In both sub-group *High quality study was considered a study awarded 7 or more stars, as standard criteria have not been established. Despite this biological plausibility, we could not find statistically significant associations between PPI use and CRC risk, which is generally consistent with previous studies. This finding could be associated with the extent of hypergastrinemia and the type of gastrin involved. 12) Usually, the cumulative duration of hypergastrinemia due to PPI therapy might be shorter than other chronic conditions such as pernicious anemia or
Sensitivity Meta-analyses
Zollinger-Ellison syndrome. 12, 29) In addition, the type of gastrin that PPI therapy increased was mainly fully processed amidated gastrin, which may have a relatively weak effect on the colorectal epithelium. 12, 13) In sensitivity meta-analyses in high quality studies, there was a tendency towards a slight increase of odds ratio between PPI use and CRC risk, although this did not reach statistical significance.
Similar results were shown in a sensitivity meta-analysis study in which an adjusted variable such as NSAIDs/aspirin use was included. In addition, when we performed the sensitivity Overall, we found that there was a non-significant increase of CRC risk among PPI users in a meta-analysis of case-control studies. Although hypergastrinemia could be an important factor in the pathogenesis of some CRCs, our study suggests that this does not lead to significant clinical risk for most PPI users. However, as the adenoma-carcinoma sequence usually is a slow progress, it is still uncertain whether PPI exposure for much longer than 5 years might increase the risk of CRC. In addition, there might be a different PPI effect on CRC in a high risk population such as those with underlying hypergastrinemia or precancerous colorectal lesions. Therefore, more prospective studies or randomized controlled trials related to PPI use and
